Breakthrough infections are less likely to lead to long COVID-19: Study

The study also provides more evidence that the two-shot Pfizer-BioNTech, Moderna and AstraZeneca vaccines offer powerful protection against symptomatic and severe disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3n9RTmX
via IFTTT